CBT, CBL, CBE and Other Reported Cannabinoids

Overview

Beyond THC and CBD, the plant makes a long list of other cannabinoids. A 2021 review says cannabis produces over 120 other cannabinoids called minor or rare, all derived, like THC and CBD, from the parent compound CBGA. [1] Some, such as CBG, CBN and CBC, have their own guides. This page covers the least studied: CBT, CBL, CBE and a few relatives. For the better-known ones, see minor cannabinoids at a glance.

This guide uses plain evidence labels: preclinical (cells/animals only), insufficient evidence, no good evidence of benefit and marketing claim. "Proper evidence not found" means we looked and found nothing usable. Nothing here is a recommendation to use any of these compounds.

CBL (cannabicyclol)

• What it is. A minor plant cannabinoid. A 2025 chemistry paper calls it largely unexplored, with its biological activity previously undocumented. [2]
• Lab findings. In laboratory binding tests, CBL showed high affinity for the serotonin 5-HT1A receptor but weak interaction with the CB1 and CB2 receptors. [2] Label: preclinical (cells/animals only).
• Mouse findings. A 2026 mouse study says data on minor cannabinoids are lacking, especially for CBL, which had not been assessed in living animals before. [3] At the amounts studied it reduced inflammation markers in mice, but the authors said effects on pain came only at high amounts that also caused side effects such as catalepsy and low body temperature. [3] Do not apply this to people.
• Human data. Proper evidence not found. We searched PubMed for cannabicyclol and found no human study.

CBT (cannabitriol)

• What it is. A minor cannabinoid. The only recent paper we found on it was a computer-modeling study that tested whether trans-CBT could interact with proteins from the monkeypox virus. [4]
• Evidence level. Preclinical at best, and really only computer modeling ("in silico"). The authors themselves say further experimental validation is needed. [4] It is not evidence that CBT treats or prevents any infection.
• Human data. Proper evidence not found.

CBE (cannabielsoin) and similar names

Proper evidence not found. We searched PubMed for cannabielsoin and found no usable study on its effects. It appears in chemistry work only, for example as one of several "heptyl" (longer side chain) acid forms putatively identified in a 2021 analysis of 49 cannabis samples. [5] A putative identification is not a measurement of amount, and nothing in that paper speaks to effects or safety.

Other reported cannabinoids

• Varin-type compounds. A 2020 systematic review of neuroprotective research covered cannabichromevarin, cannabigerivarin and related compounds, drawing on animal studies. [6] For CBDV and THCV, which have more human data, see CBDV and THCV.
• Mouse test of subjective effects. In a 2024 mouse study, all the minor cannabinoids tested, including CBCV (cannabichromenevarin), showed some binding to CB1 and CB2 receptors, but only four compounds produced THC-like effects in drug-discrimination tests: delta-9 THC, delta-8 THC, delta-10 THC (one form) and CBN. [7] Label: preclinical (cells/animals only).
• Psychiatric uses. A 2025 systematic review of minor cannabinoids in psychiatric disorders found 22 preclinical studies and one clinical study, with heterogeneous results and moderate to high risk of bias in several articles. [8] Label: insufficient evidence.

Risks, special groups and quality

For these compounds, Proper evidence not found on human safety, drug interactions or use in children, pregnancy or breastfeeding. Products that mention them are often blends where the minor compound is a small part. Any health claim that rests on cell or animal studies is a marketing claim when applied to people. The mouse study of minor cannabinoids found none of them showed anxiety- or depression-like benefit without effects on movement. [3] See medicine interactions and toxicology and cannabinoids explained.

Legal status

Not verified for CBT, CBL or CBE; we did not read a regulator page naming them. See cannabis laws by country. This is not legal advice.